Curanex Pharmaceuticals INC

Curanex Pharmaceuticals provided a Q1 2026 business update, highlighting advancements in its lead drug candidate Phyto-N for ulcerative colitis and expansion into cancer cachexia.

Curanex Pharmaceuticals has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, now until November 2, 2026.

Curanex Pharmaceuticals is expanding its drug development pipeline to include cancer cachexia, targeting a multi-billion-dollar market opportunity.

Curanex Pharmaceuticals Inc. has entered into new employment agreements with its CEO, Jun Liu, and COO, Dr. Liqin Xie, formalizing their compensation and responsibilities.

Curanex Pharmaceuticals Inc. announced the resignation of CFO Haiyan Yang and the appointment of Wanjun Zhang, effective January 1, 2026.

Curanex Pharmaceuticals Inc. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Curanex Pharmaceuticals reports Q1 2026 results, highlighting significant R&D investment and progress towards IND submission for Phyto-N, while addressing Nasdaq bid price concerns.

Curanex Pharmaceuticals reported a significantly increased net loss in Q3 2025 due to substantial R&D investments following its IPO, while also receiving a Nasdaq non-compliance notice for its share price.

Curanex Pharmaceuticals Inc. reported increased net losses for Q2 2025 but successfully closed its IPO in August, raising $12.87 million to fund botanical drug development.

Curanex Pharmaceuticals Inc. completed its IPO, raised $15.3 million, and is progressing its lead botanical drug candidate, Phyto-N, into clinical development for inflammatory diseases, despite reporting a $4.2 million net loss and internal control weaknesses.

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs, is launching an initial public offering of 3.75 million shares to raise approximately $12.1 million, aiming to advance its lead candidate Phyto-N into clinical trials for ulcerative colitis and other inflammatory conditions.

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs for inflammatory diseases, has filed an S-1/A amendment for its initial public offering to raise up to $15 million, while also extending the maturity date of a significant related-party promissory note.

Curanex Pharmaceuticals aims to raise $10 million through an IPO to fund the development of its lead botanical drug candidate, Phyto-N, and expand its research into inflammatory diseases.

Curanex Pharmaceuticals is seeking to raise capital through a $10 million IPO to fund the clinical development of its lead botanical drug candidate, Phyto-N, and pursue Nasdaq listing.

Curanex Pharmaceuticals has filed an amended registration statement for an initial public offering of 2,000,000 shares and a secondary offering of up to 1,750,000 shares by selling stockholders.

Curanex Pharmaceuticals amends its S-1 filing, detailing an IPO of 2,000,000 shares and a resale of up to 1,750,000 shares by a selling stockholder, along with updates to its incentive compensation recovery policy.